Tag Archives: decision

When will the Federal Reserve start pulling back on its extraordinary monetary stimulus? That’s the major question that Fed watchers hope to get an answer for later this afternoon, when the Federal Open Market Committee releases its updated policy decision.  Chatter has been building within the central bank over slowing the pace of its asset purchases. Since the depths of the COVID-19 pandemic, the Fed has been absorbing about $120 billion a month in U.S. Treasuries and agency mortgage-backed… Source link

Stock futures opened lower Tuesday evening as investors anxiously awaited the arrival of the Federal Reserve’s latest monetary policy decision after a volatile start to the week.  Contracts on the S&P 500 ticked down ahead of the decision. FedEx (FDX) shares fell in late trading after the shipping giant posted weaker-than-expected quarterly earnings, with supply chain disruptions and labor scarcities weighing on results. Disney (DIS) shares extended earlier losses after CEO Bob Chapek,… Source link

New York City is the first city in the nation to require proof of Covid-19 vaccinations for workers and customers at indoor restaurants, gyms and entertainment venues.  The executive order takes effect Aug. 16, but even before the mandate was announced, world renowned chef Eric Ripert said his 3-Michelin-starred seafood restaurant, Le Bernardin, would require its customers and staff to show proof of vaccination as the Delta variant spreads. Ripert told Yahoo Finance Live that despite some… Source link

Stock futures searched for direction Wednesday evening amid a mixed batch of corporate earnings results and a Federal Reserve decision that signaled the central bank was still looking for the U.S. economy to recover further before adjusting its monetary policies. Contracts on the S&P 500 edged slightly lower. The index ended the regular session in the red but hovered less than 0.5% below its recent all-time closing high. Contracts on the Dow rose, while those on the Nasdaq dipped. Shares of… Source link

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season. Big pharma companies, including Johnson & Johnson (NYSE: JNJ) and Novartis AG (NYSE: NVS) reported forecast-beating results and issued positive guidance. Preannouncements from the space were also largely positive. Moderna, Inc.’s (NASDAQ: MRNA) buoyancy spilled over into the week. The … Source link

PARIS, July 8 (Reuters) – France’s anti-trust watchdog will make a decision in the coming days over the way Google (GOOGL.O) held copyright talks with some French publishers about paying for news content, the watchdog’s head Isabelle de Silva said on Thursday. Antitrust investigators have accused Alphabet’s Google of failing to comply with the state competition authority’s orders on how to conduct negotiations with news publishers over copyright, sources who read the investigators’ report… Source link

Stock futures traded slightly higher Tuesday evening as investors looked ahead to a key monetary policy decision from the Federal Reserve. Contracts on the S&P 500 edged up. Earlier, the three major U.S. stock indexes closed out the session lower, with both the S&P 500 and Nasdaq pulling back from record highs logged earlier this week.  Traders are anxiously awaiting the conclusion of the Federal Reserve’s latest monetary policy meeting, which will culminate with a policy statement Wednesday… Source link

Stocks drifted to the downside on Monday in a muted start to the week, as traders awaited a key monetary policy decision from the Federal Reserve.  The S&P 500 ticked down after the index closed at a record high on Friday. The Dow also traded little changed to slightly lower, while the Nasdaq was roughly flat. Treasury yields ticked up, though the benchmark 10-year yield held well below 1.5%.  U.S. stocks are hovering near record levels, powered to fresh highs by a combination of rebounding… Source link

(Bloomberg) — For Biogen Inc., the Food and Drug Administration’s expected decision Monday on its Alzheimer’s drug is what a JPMorgan Chase & Co. analyst called “the mother of all binary events” — one that could send its shares veering sharply in either direction. If regulators give the company approval to market the drug, called aducanumab, the stock could surge to as much to $450, according to Wall Street analysts. Or it could tumble to $200 if the treatment is shot down,… Source link

Bloomberg SoftBank Nears End of $23 Billion Buyback, Imperiling Rally (Bloomberg) — Masayoshi Son has run almost all the way through $23 billion allocated to buy back SoftBank Group Corp. shares, raising concerns that his stock’s bull run will end without rapid intervention.The Tokyo-based company purchased more than $20 billion worth of its own shares over the past year through March, according to SoftBank filings, an unprecedented effort that more than doubled the value of the stock. Now,… Source link